ropivacaine hydrochloride injection, USP Medication Guide
()
17 PATIENT COUNSELING INFORMATION
17.1 Information for Patients and Caregivers
When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity in the anesthetized part of the body following proper administration of lumbar epidural anesthesia. Also, when appropriate, the physician should discuss other information including adverse reactions in the ropivacaine package insert.
Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.
This product’s labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
For medical information about Ropivacaine hydrochloride injection please visit www.pfizermedinfo.com or call 1-800-438-1985.
Distributed by: Hospira, Inc., Lake Forest, IL 60045 USA
LAB-1390-2.0
Find ropivacaine hydrochloride injection, USPÂ medical information:
Find ropivacaine hydrochloride injection, USP medical information:
ropivacaine hydrochloride injection, USP Quick Finder
Health Professional Information
Medication Guide
17 PATIENT COUNSELING INFORMATION
17.1 Information for Patients and Caregivers
When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity in the anesthetized part of the body following proper administration of lumbar epidural anesthesia. Also, when appropriate, the physician should discuss other information including adverse reactions in the ropivacaine package insert.
Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.
This product’s labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
For medical information about Ropivacaine hydrochloride injection please visit www.pfizermedinfo.com or call 1-800-438-1985.
Distributed by: Hospira, Inc., Lake Forest, IL 60045 USA
LAB-1390-2.0
Health Professional Information
{{section_name_patient}}
{{section_body_html_patient}}
Resources
Didn’t find what you were looking for? Contact us.
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information. 8AM-9PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Report Adverse Event
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.